DescriptionCurator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Curator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19417616 |
169.5 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ATRACURIUM BESYLATE Approved UseAtracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date1997 |
PubMed
Title | Date | PubMed |
---|---|---|
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. | 2007 Jun |
|
Anaesthetic management of post-burn contractures, a recurrent challenge from oil pipeline vandalization in Nigeria: a case report. | 2009 Dec 3 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell Lineage. | 2010 Feb 6 |
Patents
Sample Use Guides
An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED95), given as an intravenous bolus injection, is the recommended initial dose for most patients. Maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2720863
Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). When atracurium was added to the medium and the medium immediately added to hepatocytes, the leakage of LDH increased as the concentration of atracurium increased (P < 0.001 for the comparison with cells not exposed to atracurium).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175720
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
20
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
||
|
WHO-VATC |
QM03AC04
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
||
|
NCI_THESAURUS |
C66886
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
||
|
WHO-ATC |
M03AC04
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
||
|
NDF-RT |
N0000175732
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2GQ1IRY63P
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
D001279
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
2914
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
C76068
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
Atracurium
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
SUB00618MIG
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
DTXSID9043726
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
64228-79-1
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
259
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
2GQ1IRY63P
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
DB00732
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | |||
|
1218
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
ATRACURIUM
Created by
admin on Fri Dec 15 16:22:30 GMT 2023 , Edited by admin on Fri Dec 15 16:22:30 GMT 2023
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
SALT/SOLVATE (PARENT)